Nanobiotix SA (NBTX) Earnings Date & Reports

Key Takeaways

• Analysts expect Q1 2026 EPS of -$0.51, reflecting ongoing R&D investments in clinical trials.
• FY2025 revenue reached €32.6 million, with net loss narrowing to €24.0 million.
• Cash position stood at €52.8 million at year-end 2025, extending runway into early 2028 with additional financing.
• Investors watching for updates on NBTXR3 trials in NSCLC, pancreatic, and other cancers, with data readouts slated for 2026.
• Stock has surged over 800% in the past year amid positive clinical signals.
• Last quarter's EPS of -$0.45 missed consensus slightly but showed cost discipline.

Earnings Context and Why It Matters

As a clinical-stage biopharmaceutical company developing NBTXR3, a nanoparticle radioenhancer for cancer treatment, Nanobiotix S.A. (NBTX) operates in a high-stakes biotech landscape. Q1 2026 earnings will provide insights into cash burn rates following FY2025's improved financial position and non-dilutive financing. With shares up dramatically on promising Phase 1/2 data—such as 64% 12-month local progression-free survival (PFS) in NSCLC re-irradiation—this report matters for gauging progress toward pivotal trials and regulatory milestones. Investors seek confirmation of sustained runway amid R&D intensity, especially with 2026 data catalysts ahead.

Earnings Expectations

Consensus estimates point to a Q1 2026 EPS of -$0.51, based on input from analysts, wider than year-ago levels due to elevated R&D spending on NBTXR3 expansion. Revenue expectations remain modest, consistent with the company's clinical focus; FY2025 totaled €32.6 million, likely from partnerships and grants. Key metrics to watch include cash burn, updates on ongoing trials like CONVERGE (first patient dosed Q1 2025, data Q1 2026), and progress in Janssen collaboration for JNJ-1900.

Historically, NBTX has shown volatility in beats/misses; Q4 2025 EPS was -$0.45 versus -$0.39 expected, with revenue supporting operations. Guidance may reaffirm 2028 cash runway, assuming $21 million more from Healthcare Royalty financing.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Heading into Q1 earnings, sentiment is cautiously optimistic, buoyed by FY2025's narrowed losses and extended cash runway. Shares have rallied sharply YTD, reflecting enthusiasm for NBTXR3's safety/efficacy data across solid tumors. Risks include trial delays or higher-than-expected burn; historical post-earnings moves have been pronounced, with upside on positive pipeline news.

Forward Outlook and Key Factors to Monitor

Following Q1 results, attention will shift to 2026 clinical milestones for NBTXR3, including Phase 2 data in NSCLC re-irradiation, pancreatic cancer, melanoma, and esophageal cancer. Early signals—like 83% 12-month overall survival (OS) in NSCLC and 69% objective response rate (ORR) in esophageal—suggest potential, but full readouts are pivotal.

Cash management remains crucial; €52.8 million at YE2025, plus $21 million pending, funds operations into early 2028. Investors should track burn rate versus FY2025's 43% R&D reduction, partnership milestones (e.g., Janssen), and regulatory progress, such as JNJ-1900's medicinal product status in Europe.

Broader biotech dynamics, including radiotherapy advancements and M&A activity (mergers and acquisitions), could influence trajectory. Upcoming catalysts like NANORAY-312 sponsorship transfer and Curadigm platform updates warrant monitoring for demand signals and margin potential.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations